Evaluating the effectiveness and cost-effectiveness of integrating mass drug administration for helminth control with seasonal malaria chemoprevention in Ghanaian children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202312489417172

Enrollment

1200

Registered

2023-12-07

Start date

2024-05-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria Neglected Tropical Diseases - Soil Transmitted Helminths and schistosomiasis

Interventions

SMC group

SMC plus anthelminthic group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Male and female children aged 1-14 years; • Provision of written informed consent by the parent/caregiver and a positive assent by children aged = 7 years (in line with legal regulations in Ghana); • Willingness to provide finger prick blood samples, urine, and stool samples; • Residence in the study area for at least the past six months and willingness to be available in the study area for follow-up about 6 months after enrolment.

Exclusion criteria

Exclusion criteria: • Acutely ill child at the time of the drug administration; • A child whose parents/care-givers decline to provide consent; • A known HIV-positive child receiving co-trimoxazole prophylaxis; • A child who has received a dose of either Sulphadoxine-pyrimethamine (SP), amodiaquine (AQ), albendazole (ALB) or praziquantel (PZQ) during the previous six months; • A child with a known allergy to any of SP, AQ, ALB, or PZQ

Design outcomes

Primary

Measure	Time frame
Change in Haemoglobin (Hb) concentration, measured by HemoCue®,	—

Secondary

Measure	Time frame
• Incidence of clinical malaria, defined as fever of >37.5oC or a history of fever in the preceding 48 hours, and a positive malaria blood film with a parasite density of >0 per µl, detected by passive case detection during the surveillance period. • Change in prevalence of anaemia on the day of inclusion, at subsequent findings and post-intervention at the end of malaria transmission season; anaemia will be defined as Hb less than 11 g/dl. • The incidence of solicited adverse events and adverse drug reactions assessed to be related to the study medications during a period of six consecutive days after administration of study drugs. • Prevalence and density of P.falciparum infection; prevalence and density of helminth infection; and prevalence and density of malaria-helminth co-infection	—

Measure

Time frame

• Incidence of clinical malaria, defined as fever of >37.5oC or a history of fever in the preceding 48 hours, and a positive malaria blood film with a parasite density of >0 per µl, detected by passive case detection during the surveillance period. • Change in prevalence of anaemia on the day of inclusion, at subsequent findings and post-intervention at the end of malaria transmission season; anaemia will be defined as Hb less than 11 g/dl. • The incidence of solicited adverse events and adverse drug reactions assessed to be related to the study medications during a period of six consecutive days after administration of study drugs. • Prevalence and density of P.falciparum infection; prevalence and density of helminth infection; and prevalence and density of malaria-helminth co-infection

—

Countries

Ghana

Contacts

Public ContactKwaku Poku ;Dennis Asante;AduGyasi

Director Kintampo Health Research Centre;Project Coordinator

kwakupoku.asante@kintampo-hrc.org;Dennis.Adu-Gyasi@kintampo-hrc.org+233352097602;+233207028698

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026